From L-R: Scion Life Sciences co-founders Aaron Kantoff, Tadd Wessel and Samuel Hall
A new VC fund emerges with $310M to create independent, commercial biotechs
A trio of former investors from OrbiMed, Apple Tree Partners and Medicxi has come together to form a new biotech fund called Scion Life Sciences.
Scion has gathered $310 million, about $60 million over its initial target, to create six or seven new biotech companies, Aaron Kantoff, the VC fund’s co-founder and managing partner, told Endpoints News in an interview. They’re focused on quality over quantity, he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
